IHF vs XLV

IHFBiShares U.S. Healthcare Providers ETF

XLVAState Street Health Care Select Sector SPDR ETF

In short

IHF Healthcare without the drug labs. IHF tracks a US health care providers index, the insurers, hospitals and care networks that deliver and pay for care rather than invent the medicine, and it has been doing that job since 2006.

XLV Live since 1998, XLV is the original way to own health care: about 60 S&P 500 names, a 0.08% fee, and one of the busiest tickers in the sector. Big pharma and device makers, not small-cap biotech.

Stated mandate

IHF The Fund seeks to track the investment results of an index made up of U.S. equities in the healthcare providers sector. Its stated strategy is to track the Dow Jones U.S. Select Health Care Providers Index before fund fees and expenses.

XLV The fund seeks to track, before expenses, the price and yield performance of the Health Care Select Sector Index, which represents the health care sector of the S&P 500 Index.

Why people hold it

• IHF Owns the delivery-and-payment side of healthcare, not the drug pipeline. That is a genuinely different slice than a whole-sector fund, run off one index since 2006.
• Costs 0.37% a year, under the 0.50% median for health care sector ETFs.
• A multi-billion-dollar iShares fund with moderate volume: a real market on both sides of the trade.
• Lands in the upper half of the broad health care ETFs we grade, a solid showing for such a targeted mandate.

• XLV 0.08% a year against a cohort median of 0.50%. That ties it with FHLC as the cheapest in the group and edges VHT at 0.09%.
• One of the most actively traded funds in its category, which generally keeps bid-ask spreads thin whether you trade 10 shares or 10,000.
• Launched December 1998 as one of the first US sector funds, and it has tracked its S&P 500 health care index closely ever since.
• Covers the whole sector in one line: pharma, devices, providers, biotech, life-science tools and health tech. Pays quarterly.ssga.com

Worth knowing

• IHF About 60 stocks inside one corner of one sector. A narrow lineup like this can swing harder than a diversified healthcare fund.
• Broad healthcare rivals are far cheaper (VHT at 0.09%, XLV and FHLC at 0.08%). The focused mandate is what the extra fee buys.
• Distributions land quarterly. This is a growth-oriented equity slice, so income is a byproduct rather than the design.

• XLV Cap-weighted and about 60 names deep, so the largest drug and device makers carry most of the weight.ssga.com
• S&P 500 members only. Mid- and small-cap health care names sit outside the mandate.
• One sector, one set of headlines: drug pricing rules, patent expirations and policy shifts move the whole basket together.

Full IHF profile⁠

Full XLV profile⁠